The Glycocalyx in COVID-19 Patients. A Pilot Study

Completed

• Conditions: COVID-19; Endothelial Dysfunction; Coagulation Disorder

• Registration Number: NCT05137249
• Lead Sponsor: Medical University of Vienna

Brief Summary

The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS. We aim to generate first hints regarding the impact of covid-19 disease on the (damage) of the endothelial glycocalyx. Furthermore, we want to investigate the potential coagulopathies, which go along with shedding of the glycocalyx. The detection of and the relation between the severity of the disease, as well as the extent of the glycocalyx damage during the observational period, as well as the hemostatic alterations, are aim of the study.

Detailed Description

The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS. We aim to generate first hints regarding the impact of covid-19 disease on the (damage) of the endothelial glycocalyx. Furthermore, we want to investigate the potential coagulopathies, which go along with shedding of the glycocalyx. The detection of and the relation between the severity of the disease, as well as the extent of the glycocalyx damage during the observational period, as well as the hemostatic alterations, are aim of the study.Circulating plasma syndecan-1 is measured as surrogat parameter for the extent of the glycocalyx damage.

Study Timeline

• Study Start: 2020-12-01
• Primary Completion: 2021-03-01
• Study Completion: 2021-05-01
• Status Verified: 2021-11
• Study First Submitted: 2021-11-24
• Study First Submitted QC: 2021-11-24
• Last Update Submitted: 2021-11-24
• Study First Posted: 2021-11-30
• Last Update Posted: 2021-11-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• COVID-19 detected by PCR measures going along with clinical symptoms
• age > 18 years

Read More

Exclusion Criteria

• refusal of study participation

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
extent of endothelial damage	up to 2 months	circulating plasma syndecan-1 as surrogat parameter for endothelial damage is measures

Trial Locations

Locations (1)

Medical University of Vienna; 🇦🇹 Vienna, Austria